Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Consider This Method to Measure JAK2 Status in MF

Leuk Res; 2017 Dec; Strati, Benton, et al

Publish date:: December 10, 2017

Saliva testing is an easier and possibly more reliable method than peripheral blood for measuring JAK2 status and assessing V617F allelic burden in transfusion-dependent patients with myelofibrosis (MF), according to a prospective study involving 167 individuals. Investigators used both methods simultaneously on participants who had MF. Among the results:

Concordance between the 2 methods was 96%.
Sensitivity and specificity were 100% and 90%, respectively.
Ongoing transfusion dependency was the only factor linked with false positive results from saliva testing.

Citation:

Strati P, Benton CB, Manshouri T, et al. JAK2V617F detection and allele burden measurement in saliva vs peripheral blood in patients with myelofibrosis. Leuk Res. 2017;63:53-55. doi:10.1016/j.leukres.2017. 10.016.

This Week's Must Reads

Consider potential cognitive complications prior to androgen deprivation therapy,

Diabetes raises risk of prostate cancer mortality in obese men,

Salivation inhibition fails to reduce radioiodine toxicity in prostate cancer,

Highest positive surgical margin predicts poor survival after prostatectomy,

Young minority men are underinformed about prostate cancer screening,

Must Reads in Hematologic Malignancies

Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10

Prognostic Score System for Patients with PMF, J Clin Oncol; ePub 2017 Dec 9; Gugliemelli, et al

These Patients Are More Apt to Be Depressed, Ann Hematol; ePub 2017 Dec 7; Shreders, et al

Survival Length Shortest in These Patients with MF, Eur J Haematol; ePub 2017 Dec 11; Masarova, et al

The Value of Ruxolitinib Before and After AlloSCT, Blood; ePub 2017 Dec 7; Poulose, Malysz, et al